

Clinical trials of various drugs

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
various drugs vs placebo			
HARP , 1994 [NCT00000461] n=40/39 follow-up: 2.5 years	Various drugs (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil stepwise as needed to reach the specified goal (total cholesterol <or = 4.1 mmol/L, ratio of LDL/high-density-lipoprotein [HDL] cholesterol <or = 2.0) versus placebo	normocholesterolaemic patients with coronary heart disease	Parallel groups open
various drugs vs usual care			
SCRIP , 1994 [NCT00000508] n=145/155 follow-up: 4.0 years	multifactor risk reduction (Various drugs) versus usual care	patients with angiographically defined coronary atherosclerosis	Parallel groups open

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with prior MI or with CHD at <http://www.trialresultscenter.org/go-Q12>
- cholesterol lowering intervention for cardiovascular prevention in all chronic situations at <http://www.trialresultscenter.org/go-Q154>

References

HARP, 1994:

Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet 1994;344:1182-6 [7934538]

SCRIP, 1994:

Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90 [8124838]